About Helomics
Helomics is a company based in Pittsburgh (United States) founded in 1995 was acquired by Predictive Oncology in June 2018. Helomics has raised $195.59 million across 9 funding rounds from investors including Predictive Oncology, Draper Triangle and HealthCare Royalty Partners. The company has 13 employees as of December 31, 2018. Helomics offers products and services including AI/ML Platform, 3D Tumor Models, and ChemoFx Testing. Helomics operates in a competitive market with competitors including Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
- Headquarter Pittsburgh, United States
- Employees 13 as on 31 Dec, 2018
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$195.59 M (USD)
in 9 rounds
-
Latest Funding Round
$3 M (USD), Series E
Apr 23, 2018
-
Investors
Predictive Oncology
& 11 more
-
Employee Count
13
as on Dec 31, 2018
-
Acquired by
Predictive Oncology
(Jun 28, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Helomics
Helomics offers a comprehensive portfolio of products and services, including AI/ML Platform, 3D Tumor Models, and ChemoFx Testing.
Platform predicts drug responses using tumor samples and machine learning.
Models mimic patient responses for oncology drug development testing.
Service for tumor drug-response and genomic biomarker analysis.
Funding Insights of Helomics
Helomics has successfully raised a total of $195.59M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $3 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Helomics
Helomics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Predictive Oncology, Draper Triangle and HealthCare Royalty Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare royalty investments are focused on US and UK markets.
|
Locked | Locked | Locked | |
|
Early-stage VC investments are made in US tech companies.
|
Locked | Locked | Locked | |
|
US focused early-stage VC firm investing in tech & life sciences start-ups
|
Locked | Locked | Locked |
Investor details for Helomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Helomics
Investment portfolio details for Helomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Helomics
Detailed financials for Helomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Helomics Comparisons
Peer comparison for Helomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Helomics
Helomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
Detailed competitors of Helomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Helomics
Complete news archive for Helomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Helomics
Helomics was founded in 1995 and raised its 1st funding round 6 years after it was founded.
Helomics is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Helomics is a funded company, having raised a total of $195.59M across 9 funding rounds to date.
As of Dec 31, 2018, the latest employee count at Helomics is 13.
Helomics was established in 1995 in Pittsburgh, United States, within the biotechnology sector focused on oncology. An AI-driven platform is operated to create targeted therapies for cancer patients. Proprietary technology and data pipelines are maintained to deliver services to pharmaceutical and diagnostic firms, supporting the advancement of precision medicine solutions in the region.
Helomics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Helomics offers AI/ML Platform, 3D Tumor Models, and ChemoFx Testing.
Helomics has 12 investors. Key investors include Predictive Oncology, Draper Triangle, HealthCare Royalty Partners, Adams Capital Management, and Birchmere Ventures.